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Abstract
Background:  We compared the type and duration of diabetes mel-
litus (DM), patient demography, high sensitivity C-reactive protein 
(hsCRP), Homocysteine and other variables with IMT, to determine 
if these markers were correlated in diabetes (in whom technetium 
myocardial perfusion scan were negative) and would it be appropri-
ate biomarkers for arthrosclerosis detection in this group of diabet-
ics.
Methods:  Forty patients with DM, without CHD history, were 
screened with stress sintigraphy imaging using 2 days stress/rest 
Technetium 99 tetrafosmin protocol, employing the standard Bruce 
protocol. Echocardiography study requested for each patient, two 
blood samples for hsCRP, were requested for each candidate three 
weeks apart, Lipid profiles, plasma homocysteine, and hemoglo-
bin A1C were also requested. Finally Intima–media thickness were 
measured for all patients.
Results:  There were no relationships between hsCRP level and 
DM duration or with the type of DM; also there were no relation 
between DM duration and homocysteine or between DM type and 
Homocysteine. Intimal media thickness was increased proportion-
ally with the serum level of Homocysteine.
Conclusions:  This study did not show any role for the inflamma-
tory markers in predicating the presence of coronary artery disease 
in participants with DM, without medium size artery disease, which 
may support that DM is not the only player in initiating atheroscle-
rosis.
Keywords:  Diabetes mellitus; Inflammatory markers; C-reactive 
protein; Myocardial ischemia; Homocysteine; Intima-media thick-
ness
Introduction
  Cardiovascular disease is the leading cause of mortality 
in diabetic patients, accounting as many as 80% of diabetic 
patient deaths [1].  The risk of myocardial infarction (MI) in 
diabetic patients is similar non-diabetic patients with a his-
tory of a previous MI [2].  Post-mortem studies on diabetics 
suggest a high prevalence of coronary atherosclerosis, even 
among those without clinical coronary heart disease (CHD).   
Advanced coronary lesions are found in about 75% of dia-
betic patients without clinically apparent CHD and >50% of 
asymptomatic individuals also had multi-vessel disease [3].   
Moreover, the prevalence of silent ischemia among asymp-
tomatic diabetics is high, ranging from 20 to >50% [4].  The 
incidence of Diabetes Mellitus (DM) among Qatari patients 
with acute myocardial infarction is 54% [5].  
  Biomarkers are used for risk assessment stratification 
for patient. These include increased high-sensitivity C-reac-
tive protein (hsCRP), an inflammation marker; homocyste-
ine, indicative of endothelial function and oxidative stress; 
and urinary albumin : creatinine ratio, an indicator of glo-
merular  endothelial  function  [6].  Increased  intima-media 
thickness (IMT) of the common carotid artery, measured by 
high resolution B-mode ultrasound imaging, occurs early in 
the atherosclerosis process and generally precedes plaque 
development and stenosis in the arterial wall as a marker 
for the presence of atherosclerosis. Also, IMT is associated 
with a higher prevalence of symptomatic and asymptomatic 
CHD and correlates with future development of myocardial 
infarction and stoke [7]. We compared the type and dura-
tion of diabetes mellitus (DM), patient demography, HsCRP, 
Homocysteine and other variables with IMT to determine if 
these markers were correlated in diabetes; would it be ap-
propriate biomarkers for early arthrosclerosis detection in 
diabetics and lastly their behavior and inter- relationship of 
these markers with diabetes mellitus disease process.
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Materials and Methods
  Consecutive forty patients with DM, with no history 
of  ischemic  heart  disease  were  referred  from  endocrinol-
ogy clinics and participated in the study from January 2003 
till November 2006. A written consent was obtained by all 
participants.  Medical  history,  physical  examination,  body 
weight, height, and vital signs were all recorded.  Electro-
cardiogram and Chest X-ray were performed for all patients. 
Patients were screened with stress sintigraphy imaging us-
ing 2 days stress/rest Technetium 99 tetrafosmin protocol, 
employing the standard Bruce protocol. The Single photon 
emission computed tomography (SPECT) images were ac-
quired using a dual-head gamma camera (E. cam, Siemens) 
to exclude CHD and medium size artery disease. Echocar-
diography was performed for patients using Acuson sequoia 
C512, to assess the average ejection fraction (EF), measured 
by 2 and 4 chambers and apical views. Two blood samples for 
hsCRP, after excluding aberrant infections by history, were 
requested for each candidate three weeks apart and were ana-
lyzed by IMMAGE kite, Immunochemistry system (Beck-
man Coulter). Lipid profiles, plasma homocysteine, and he-
moglobin A1C were also requested. Intima-media thickness 
was measured for each patient by High resolution B mode, 
colour Doppler, and pulse Doppler Ultrasonography of both 
carotid arteries were performed with an ultrasound machine 
(Logiq 9, General Electric Company) equipped with a 10 
MHz linear array transducer. Patients were examined in the 
supine position with the head tilted backwards. After the 
carotid arteries were located by transverse scans the probe 
was rotated 90° to obtain and record a longitudinal image 
of the anterior and posterior walls. The maximum IMT was 
measured at the far wall of the both common carotid arter-
ies during end diastole, 2 cm proximal to the bifurcation, 
from a longitudinal scan plane that showed the intima-media 
boundaries most clearly. The longitudinal view of the nor-
mal carotid wall demonstrates two nearly parallel echogenic 
lines. The inner line represents the lumen-intima interface 
and the outer line represents the media adventitia interface. 
The distance between these lines is the combined thickness 
of intima-media complex (I-M complex). IMT may be the 
most sensitive marker for the earliest stages of atheroscle-
rosis and it is considered to be a marker of generalized ath-
erosclerosis. 
  In healthy adults, IMT ranges from 0.25 to 1.5 mm 
[8], and values >1.0 mm are often regarded as abnormal [9]. 
IMT has been proposed as a quantitative index of athero-
sclerosis of value in monitoring disease progression and the 
effects of treatment and as a surrogate end point in clinical 
trials. Average measurements of left and right carotid arteries 
were used. The study protocol was reviewed and approved 
by the institutional review board of the Hamad Medical Cor-
poration. All tests and procedures were free of charge for 
participants. The data were handled by the biostatistics de-
partment, Hamad Medical corporation using SPSS software, 
the P value were calculate by Chi-square, T test, Correlation 





  Forty patients were enrolled in the study. Two patients 
had  positive results with stress technetium myocardial per-
fusion scan were excluded from the study; while thirty eight 
patients participated in the study had negative results for 
myocardial radio-isotope scan were included in the study, 
17 females and 21 males, with mean age of 54 years (41-
87 years of age). Fifteen cases were DM type one while the 
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Table 1. Baseline characteristics of study participants
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rest were DM type two. DM duration ranged from 2 to 30 
years, with an average of 11.3 years. Twenty six cases were 
hypertensive ranging from 1 to 15 years, with an average of 
6.5 years. Body mass index (BMI) ranged from 22.7 - 48.59, 
with an average of 30.67. Three cases had a normal BMI, 
while fifteen cases were overweight with BMI > 25, and re-
maining were obese with BMI > 30. Out of 40 patients, 32 
patients never smoked, six were current smokers, and only 
two patients were ex-smokers. Ejection fraction ranged from 
50 to 72%, average of 63.2% (Table 1). None of the patients 
showed wall motion abnormalities.
High sensitivity C-reactive protein (hsCRP) analysis
  The two cases with positive stress sintigraphy imag-
ing for ischemic heart disease had HsCRP level of 0.274 and 
0.417 mg/dl respectively both values were below the refer-
ence value of < 0.744 mg/dl (P = 0.35)   
  More than half of the cases (26 patients) showed high 
sensitivity C-reactive protein levels (hsCRP) below refer-
ence values and only 12 cases had hsCRP levels more than 
0.744 mg/dl. HsCRP levels were ranging from 0.327 to 6.3 
mg/dl, with an average of 0.9777 mg/dl. There was no rela-
tionship between hsCRP level and DM duration the Pearson 
Correlation co-efficient equal to 0.204 and P value of 0.225 
(Fig. 1) or with the type of DM (P = 0.37) (Table 2).  Also, no 
relationship was found between hsCRP and BMI with Pear-
son Correlation co-efficient of –0.112 and P value of 0.527. 
Finally no relation was found between CRP and smoking in 
this present study, (5 smoker and the rest were none smok-
ers), P = 0.37.
Homocysteine analysis
  Homocysteine  levels  were  measured  for  all  patients 
and ranged from 3 to 93 μm/L, average was 12.217 μm/L. 
Only five cases were higher than the reference value of 20.44 
μm/L. The two cases with positive stress sintigraphy imag-
ing for ischemic heart disease had Homocysteine level of 7 
and 11 μm/L respectively which is below the reference value 
of 20.44 μm/L (P = 0.058).
  There was no relation between DM duration and ho-
mocysteine (P = 0.92; Fig. 2) or between DM type and ho-
mocysteine (P = 0.53) (Table 2).  Also, there were no rela-
tions between CRP and homocysteine levels in this sample 
with Pearson Correlation Co-efficient of –0.64 and P value 
of 0.708.
Intimal media thickness (IMT) analysis
  Intimal media thickness (IMT) was measured for all 
cases by the same operator. Values >1.0 mm are regarded as 
abnormal [9].  IMT values ranged from 0.45 mm to 1.8 mm, 
average of 0.88 mm. Sixteen cases had an IMT of equal to 
or less than 1mm, while the rest (22 cases) were more than 1 
mm. Neither DM duration nor the DM type related to IMT (P 
= 0.971, P = 0.49, respectively) (Table 2). Only one case with 
positive stress sintigraphy imaging had the IMT measured 
with avalue of 1.1mm making the P = 0.39.
Figure 1. Relationship between mean hsCRP and DM duration. Axis X represents duration of DM in years, axis Y 
represents level of hsCRP in mg/dl.
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  Intimal media thickness was increased proportionally 
with the serum level of homocysteine with Pearson correla-
tion co-efficient of 0.414 and P value of 0.050 (Fig. 3).
 
Hemoglobin A1c analysis
  The Hemoglobin A1c, ranged from 5.1 to 11.2 %, with 
an average of 7.6%. Out of the thirty-eight  cases with no 
IHD, only  two cases had HbA1c less than 6%.  HbA1c lev-
els suggest that most of our patients were not effectively 
controlling their blood glucose levels. This should theoret-
ically have an impact on CRP; but we did not detect any 
significant differences. HbA1c was used as a parameter for 
overall blood glucose control. Regarding the two cases with 
positive stress sintigraphy imaging, one had HbA1c level of 
5.8 while the other got a level of 9.1%.
Discussion
  
  Diabetes Mellitus leads to excess free fatty acids, hy-
perglycemia, and insulin resistance together these increase 
oxidative stress, protein kinase C activation, and receptors 
for advanced glycation end product activation. The total sum 
of these effects results endothelium dysfunction, mediated 
through many pro-inflammatory factors, causing inflamma-
tion and atherosclerosis [10]. This study examined inflam-
matory markers and IMT in DM patients without medium 
size artery disease, to determine if these markers were cor-
related with diabetes and would be appropriate biomarkers 
for early arthrosclerosis detection and whether there is inter-
relationship between these factors and their behavior with 
the disease process.
  Two cases were positive for IHD confirmed by radio-
isotope myocardial scan and in both cases the results for in-
flammatory markers were low; but due to small sample, a 
solid conclusion regarding the relation between the level of 
inflammatory markers and presence of CAD should not be 
made.
  C-reactive protein (CRP) is an acute-phase reactant 







HsCRP 0.225 NS 0.37 NS
Homocysteine 0.92 NS 0.53 NS
IMT 0.971 NS 0.49 NS
Table 2. Statistical relationship between Diabetes mellitus 
duration and type with different inflammatory markers and 
arterial Intimal media thickness
NS for not significant.
Figure 2. Relationship between homocysteine and DM duration. Aixs X represents the duration of DM in years, axis Y represents 
the Homocystine level in µmol/l.
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uli. Circulating at low concentrations in healthy individuals, 
CRP rises dramatically in response to infection, inflamma-
tion, and injury. CRP is used in clinical settings as part of the 
diagnostic workup to monitor disease status and treatment 
results. Studies suggest elevated CRP levels may predictive 
for cardiovascular disease and diabetes [11, 12]. In agree-
ment with our findings, Haverkate et al [13] from the Angina 
Pectoris Study group, found no association between CRP 
and diabetes. The lack of association maybe due to increased 
BMI in DM and the presence of acute and chronic infections 
like diabetic foot [14-16].   
  Although  previous  studies  showed  CRP  was  corre-
lated with BMI [13, 17], the magnitude of the association 
was not always presented. The European Concerted Action 
on  Thrombosis  and  Disabilities  (ECAT)  Angina  Pectoris 
Study found that CRP and BMI were significantly associated 
among 2,121 patients with angina pectoris, but no detailed 
analyses were presented [13]. The reasons for the apparent 
association between CRP and BMI are not clear. In the pres-
ent study, we did not find a relationship between DM dura-
tion (without CHD) and BMI or a relationship between CRP 
and BMI.  
  Why other studies found an association between DM, 
BMI and CRP could be due to several factors. First, indi-
viduals with obesity are at increased risk for various chronic 
diseases,  several  are  also  characterized  by  elevated  CRP. 
Second, subclinical disease may be responsible for the ob-
served  association.  Third,  obesity  could  be  accompanied 
by an inflammatory component unrelated to accompanying 
clinical or subclinical pathology.
 In the Cardiovascular Health Study, CRP was signifi-
cantly associated with diabetes in nearly 190 subjects who 
never  smoked,  but  not  in  nearly  180  subjects  who  had 
smoked  [18]. In the present study, such relationship was 
not found likely due to the small participant number and few 
participants were smokers as others have same findings [13], 
this brings the need for more intensive research regarding 
these negative results with larger groups of patients.
  Clinical evaluation for homocysteine may be an indica-
tor for atherosclerosis when combined with a family history 
of atherothrombosis, in the absence of other major risk fac-
tors. Homocysteine evaluation is also likely to more prev-
alent among patients with renal failure [19]. Patients with 
severe hyperhomocysteinemia may have a variety of symp-
toms including a high incidence of vascular pathology that 
may result in early death from myocardial infarction, stroke, 
or pulmonary embolism. Biochemical and pathological stud-
ies in homocystinuric children concluded that elevated blood 
homocysteine  may  cause  early  arteriosclerosis.  Observa-
tions in nearly 80 clinical and epidemiological studies sug-
gest elevated homocysteine is a risk factor for atherosclerotic 
vascular disease and for arterial and venous thromboembo-
lism [19]. In the present study, there was neither any rela-
tion between DM type and duration with homocysteine nor 
Figure 3. Relation between carotid intimal media thickness and Homocysteine levels. Axis A represent Homocystine level in 
µmol/l, axis B represent Intimal Media thickness in mm, axis C represent the cases.
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any relation between CRP and Homocysteine; yet we have 
some cases had DM for more than 30 years. These findings 
could be explained on a genetic variation and predisposition 
as stated below.
  Increased intima-media thickness (IMT) of the carotid 
artery, as measured by high-resolution B-mode ultrasound 
imaging, occurs early in the atherosclerotic process and pre-
cedes the development of plaque and stenosis in the arterial 
wall [20, 21]. Hence associated with a higher prevalence of 
symptomatic and asymptomatic CHD and predisposes pa-
tients to myocardial infarction or stroke [22].
  Diabetic patients exhibit a higher degree of early ath-
erosclerosis than normal glucose-tolerant subjects, matched 
for age and sex. Data suggests hyperglycemia, together with 
other  risk  factors  (particularly  dyslipidemia),  may  cause 
intimal-medial  thickening  in  the  early  phases  of  diabetes 
[23]. Yet we did not find a relationship between the duration 
or type of DM with IMT. However, DM’s involvement in 
atherosclerosis is complex and involves genetic predisposi-
tions, as well as, environmental influences [7].  The level of 
Homocysteine increased proportionally in this study with the 
IMT and this finding is consistent with many other studies 
that document the relation between these parameters and its 
relation to DM and IHD and the effect of such combination 
on atherosclerosis progression, thrombo-embolism and total 
cardiovascular morbidity and mortality [24-27].
   The ratio of total cholesterol to high density lipoprotein 
is regarded as one of the strongest independent predictors 
for developing peripheral arterial disease [28].  In this pres-
ent study, we found no relationship between the TC/HDL-C 
with duration and DM type and no correlation between IMT, 
BMI, and CRP with TC/HDL-C. These findings are reason-
able as study participants did not exhibit medium size arte-
rial disease. Also, this study did not show any role of inflam-
matory markers in participants with DM, without medium 
size artery disease, which may support that inflammation in 
DM is not the solo player in initiating atherosclerosis but 
other factors may have a role in accelerating the atheroscle-
rosis process as other studies had suggested [7]. This find-
ing is not accepted by many endocrinologist or cardiologists; 
hence we need more work concentrating on these negative 
results to clear up the clouds. As negative results will not 
initiate more research as positive results which some times 
taken as granted; but in this critical area of high risk patients 
one ought to be more accurate in predicting and even treating 
cases not on solid grounds. 
  The small sample of the study due to difficulties in lo-
gistics and patients acceptance to participate in such kind of 
studies limits the value and power of the results; yet it may 
contribute to the flow of the studies made in the same line 
and add some data to the global effort for early detection and 
monitor the progression of atherosclerosis. We combined the 
two types of DM in the study together and we did not look 
for statin therapy in our group of patients as we had small 
sample that dividing this sample will make the results more 
biased.
Acknowledgements
   The authors declare no conflicts of interest.
References
1.  Bonow RO, Bohannon N, Hazzard W. Risk stratification 
in coronary artery disease and special populations. Am J 
Med 1996;101(4A):4A17S-22S; discussion 22S-24S.
2.  Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso 
M. Mortality from coronary heart disease in subjects 
with type 2 diabetes and in nondiabetic subjects with 
and without prior myocardial infarction. N Engl J Med 
1998;339(4):229-234.
3.  Goraya  TY,  Leibson  CL,  Palumbo  PJ,  Weston  SA, 
Killian JM, Pfeifer EA, Jacobsen SJ, et al. Coronary 
atherosclerosis in diabetes mellitus: a population-based 
autopsy study. J Am Coll Cardiol 2002;40(5):946-953.
4.  Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey 
JA, Barrett EJ, Taillefer R, et al. Detection of silent myo-
cardial ischemia in asymptomatic diabetic subjects: the 
DIAD study. Diabetes Care 2004;27(8):1954-1961.
5.  Jassim Al Suwaidi Ab, HA Al Binali, R Hajar, I Moham-
med. The incidance of Diabetes Mellitus among qatari 
patients with acute myocardial infarction (1991-2001). 
unpublished data 1991-2001.
6.  Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, New-
ton-Cheh C, Jacques PF, et al. Multiple biomarkers for 
the prediction of first major cardiovascular events and 
death. N Engl J Med 2006;355(25):2631-2639.
7.  Pannacciulli N, De Pergola G, Ciccone M, Rizzon P, 
Giorgino F, Giorgino R. Effect of family history of type 
2 diabetes on the intima-media thickness of the com-
mon carotid artery in normal-weight, overweight, and 
obese  glucose-tolerant  young  adults.  Diabetes  Care 
2003;26(4):1230-1234.
8.  Veller MG, Fisher CM, Nicolaides AN, Renton S, Ger-
oulakos G, Stafford NJ, Sarker A, et al. Measurement of 
the ultrasonic intima-media complex thickness in nor-
mal subjects. J Vasc Surg 1993;17(4):719-725.
9.  Salonen  JT,  Salonen  R.  Ultrasound  B-mode  imaging 
in observational studies of atherosclerotic progression. 
Circulation 1993;87(3 Suppl):II56-65.
10.  Beckman JA, Creager MA, Libby P. Diabetes and Ath-
erosclerosis: Epidemiology, Pathophysiology, and Man-
agement. 2002. p. 2570-2581.
11.  Festa A, D’Agostino R, Jr., Tracy RP, Haffner SM. El-
evated levels of acute-phase proteins and plasminogen 
activator inhibitor-1 predict the development of type 2 
   99                                    100J Clin Med Res  •  2009;1(2):95-101          Inflammatory Markers in Diabetics
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
diabetes:  the  insulin  resistance  atherosclerosis  study. 
Diabetes 2002;51(4):1131-1137.
12.  Schmidt  MI,  Duncan  BB,  Sharrett AR,  Lindberg  G, 
Savage PJ, Offenbacher S, Azambuja MI, et al. Markers 
of inflammation and prediction of diabetes mellitus in 
adults (Atherosclerosis Risk in Communities study): a 
cohort study. Lancet 1999;353(9165):1649-1652.
13.  Haverkate F, Thompson SG, Pyke SD, Gallimore JR, 
Pepys MB. Production of C-reactive protein and risk of 
coronary events in stable and unstable angina. European 
Concerted Action on Thrombosis and Disabilities Angi-
na Pectoris Study Group. Lancet 1997;349(9050):462-
466.
14.  McMillan DE. Increased levels of acute-phase serum 
proteins  in  diabetes.  Metabolism  1989;38(11):1042-
1046.
15.  Ueta E, Osaki T, Yoneda K, Yamamoto T. Prevalence 
of diabetes mellitus in odontogenic infections and oral 
candidiasis: an analysis of neutrophil suppression. J Oral 
Pathol Med 1993;22(4):168-174.
16.  van Eeden SF, Strachan AF, Hough SF. Circulating acute 
phase reactive proteins as indicators of infection in poor-
ly controlled diabetes mellitus. Diabetes Res Clin Pract 
1988;5(2):99-105.
17.  Mendall MA, Patel P, Ballam L, Strachan D, Northfield 
TC. C Reactive protein and its relation to cardiovascu-
lar risk factors: a population based cross sectional study. 
1996. p. 1061-1065.
18.  Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, 
Cornell ES, Kuller LH. Lifetime Smoking Exposure Af-
fects the Association of C-Reactive Protein with Cardio-
vascular Disease Risk Factors and Subclinical Disease 
in Healthy Elderly Subjects. 1997. p. 2167-2176.
19.  Malinow MR, Bostom AG, Krauss RM. Homocyst(e)
ine,  diet,  and  cardiovascular  diseases:  a  statement 
for  healthcare  professionals  from  the  Nutrition  Com-
mittee,  American  Heart  Association.  Circulation 
1999;99(1):178-182.
20.  Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Inti-
mal plus medial thickness of the arterial wall: a direct 
measurement  with  ultrasound  imaging.  Circulation 
1986;74(6):1399-1406.
21.  Crouse JR, 3rd, Craven TE, Hagaman AP, Bond MG. 
Association of coronary disease with segment-specific 
intimal-medial thickening of the extracranial carotid ar-
tery. Circulation 1995;92(5):1141-1147.
22.  O’Leary  DH,  Polak  JF,  Kronmal  RA,  Manolio  TA, 
Burke GL, Wolfson SK, Jr. Carotid-artery intima and 
media thickness as a risk factor for myocardial infarc-
tion and stroke in older adults. Cardiovascular Health 
Study  Collaborative  Research  Group.  N  Engl  J  Med 
1999;340(1):14-22.
23.  Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, 
Schaper F, Henkel E, Siegert G, Hanefeld M. Increased 
intimal-medial thickness in newly detected type 2 diabe-
tes: risk factors. Diabetes Care 1999;22(2):333-338.
24.  Ndrepepa G, Kastrati A, Braun S, Koch W, Kolling K, 
Mehilli J, Schomig A. A prospective cohort study of 
predictive value of homocysteine in patients with type 
2 diabetes and coronary artery disease. Clin Chim Acta 
2006;373(1-2):70-76.
25.  Bondar IA, Pikalov IV, Pechkovskii EV, Alina AR. [Hy-
perhomocysteinemia in coronary artery disease and he-
mostasis disorders in patients with type 2 diabetes mel-
litus]. Klin Med (Mosk) 2007;85(5):30-33.
26.  Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa 
T. Elevated plasma homocysteine level is an indepen-
dent predictor of coronary heart disease events in pa-
tients with type 2 diabetes mellitus. Ann Intern Med 
2004;140(2):94-100.
27.  Haraki T, Takegoshi T, Kitoh C, Kajinami K, Wakasugi 
T,  Hirai  J,  Shimada T,  et al.  Hyperhomocysteinemia, 
diabetes mellitus, and carotid atherosclerosis indepen-
dently increase atherosclerotic vascular disease outcome 
in Japanese patients with end-stage renal disease. Clin 
Nephrol 2001;56(2):132-139.
28.  Ridker PM, Stampfer MJ, Rifai N. Novel Risk Factors 
for Systemic Atherosclerosis: A Comparison of C-Reac-
tive Protein, Fibrinogen, Homocysteine, Lipoprotein(a), 
and  Standard  Cholesterol  Screening  as  Predictors  of 
Peripheral Arterial Disease. JAMA 2001;285(19):2481-
2485.
   101                                   